Targeting a protein complex to treat leukemia
Official title: Targeting PRC1 in leukemia
Funded at University of Michigan at Ann Arbor · NIH-10913518 · Data updated 2026-11-12
This study is exploring new ways to treat acute leukemia by developing small molecules that target a specific protein involved in the growth of cancer cells, with the hope of making these cells easier to treat.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $593,733 |
| NIH project number | 5R01CA282082-02 |
| Project ID | NIH-10913518 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute leukemia, particularly those with treatment-resistant forms of the disease.
✕Less likely to help
Patients with other types of cancer or those who do not have acute leukemia may not benefit from this research.
What this research studies
This research focuses on developing new treatments for acute leukemia by targeting a specific protein complex known as PRC1, which plays a crucial role in the growth and survival of leukemic stem cells. The approach involves creating small molecules that inhibit the activity of PRC1, potentially leading to the differentiation and elimination of these resistant cancer cells. By using advanced screening techniques and medicinal chemistry, the researchers aim to discover effective compounds that can induce changes in leukemic cells, making them more susceptible to treatment. This innovative strategy could provide a new avenue for combating acute leukemia, which is often difficult to treat with existing therapies.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively target and eliminate resistant leukemic stem cells, improving outcomes for patients with acute leukemia.
How similar studies have gone: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Cierpicki, Tomasz — University of Michigan at Ann Arbor
- Study coordinator: Cierpicki, Tomasz
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.